J
Judith M. Kramer
Researcher at Duke University
Publications - 65
Citations - 7038
Judith M. Kramer is an academic researcher from Duke University. The author has contributed to research in topics: Clinical trial & Myocardial infarction. The author has an hindex of 31, co-authored 65 publications receiving 6734 citations. Previous affiliations of Judith M. Kramer include Food and Drug Administration & Durham University.
Papers
More filters
Journal ArticleDOI
Scientific Evidence Underlying the ACC/AHA Clinical Practice Guidelines
TL;DR: Recommendations issued in current ACC/AHA clinical practice guidelines are largely developed from lower levels of evidence or expert opinion, and the proportion of recommendations for which there is no conclusive evidence is also growing.
Journal ArticleDOI
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.
Eric L. Eisenstein,Kevin J. Anstrom,David F. Kong,Linda K. Shaw,Robert H. Tuttle,Daniel B. Mark,Judith M. Kramer,Robert A. Harrington,David B. Matchar,David E. Kandzari,Eric D. Peterson,Kevin A. Schulman,Robert M. Califf +12 more
TL;DR: In this paper, the authors evaluated the association between clopidogrel use and long-term clinical outcomes of patients receiving drug-eluting stents and bare-metal stents for treatment of coronary artery disease.
Journal Article
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. Commentary
Eric L. Eisenstein,Kevin J. Anstrom,David F. Kong,Linda K. Shaw,Robert H. Tuttle,Daniel B. Mark,Judith M. Kramer,Robert A. Harrington,David B. Matchar,David E. Kandzari,Eric D. Peterson,Kevin A. Schulman,Robert M. Califf,Dean J. Kereiakes +13 more
TL;DR: The extended use of clopidogrel in patients with DES may be associated with a reduced risk for death and death or MI, and the appropriate duration for clopIDogrel administration can only be determined within the context of a large-scale randomized clinical trial.
Journal ArticleDOI
What clinicians should know about the QT interval.
TL;DR: Although the use of QT-prolonging medications can predispose to torsades de pointes, there is a relative paucity of information that can help clinicians and patients make optimal informed decisions about how to minimize the risk of this serious complication.
Journal ArticleDOI
Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary Artery Disease
L. Kristin Newby,Nancy M. Allen LaPointe,Anita Y. Chen,Judith M. Kramer,Bradley G. Hammill,Elizabeth R. DeLong,Lawrence H. Muhlbaier,Robert M. Califf +7 more
TL;DR: Use of evidence-based therapies for CAD has improved but remains suboptimal, and considerable attention must also be focused on understanding and improving long-term adherence.